Molekulargenetisches Labor
Zentrum für Nephrologie und Stoffwechsel
Moldiag Erkrankungen Gene Support Kontakt

Störungen im Cytochrom P450-System

Über das Cytochrom P450-System werden viele verschiedene Arzneimittel metabolisiert. Dies erklärt dass viele Medikamenten Interaktionen und Nebenwirkungen aus Interfrenzen in den gemeinsamen Stoffwechselwegen resultieren.

Gliederung

Genetische Einflüsse auf Arzneimittel-Verträglichkeit
Coumarin-Resistenz
Hepatitis C-Therapieansprechbarkeit
Störungen im Cytochrom P450-System
CYP1A2
CYP2A6
CYP2C9
CYP2D6
CYP3A4
CYP4F2
Siponimod-Intoleranz
CYP2C9

Referenzen:

1.

Paolini M et al. (1999) Co-carcinogenic effect of beta-carotene.

external link
2.

Nebert DW et al. (1987) P450 genes: structure, evolution, and regulation.

external link
3.

Daly AK et al. (1992) Deficient nifedipine oxidation: a rare inherited trait associated with cystic fibrosis kindreds.

external link
4.

Inoue K et al. (1992) Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization.

external link
5.

Wolf CR et al. (1992) Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility.

external link
6.

Wrighton SA et al. (1992) The human hepatic cytochromes P450 involved in drug metabolism.

external link
7.

Forrester LM et al. (1990) Evidence for involvement of multiple forms of cytochrome P-450 in aflatoxin B1 metabolism in human liver.

external link
8.

Shimada T et al. (1989) Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver.

external link
9.

Wrighton SA et al. (1989) Isolation and characterization of human fetal liver cytochrome P450HLp2: a third member of the P450III gene family.

external link
10.

Spurr NK et al. (1989) The human cytochrome P450 CYP3 locus: assignment to chromosome 7q22-qter.

external link
11.

Brooks BA et al. (1988) The gene CYP3 encoding P450pcn1 (nifedipine oxidase) is tightly linked to the gene COL1A2 encoding collagen type 1 alpha on 7q21-q22.1.

external link
12.

Renwick AG et al. (1988) The pharmacokinetics of oral nifedipine--a population study.

external link
13.

Gonzalez FJ et al. (1988) Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase.

external link
14.

Schellens JH et al. (1988) Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects.

external link
15.

Molowa DT et al. (1986) Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver.

external link
16.

Watkins PB et al. (1985) Identification of an inducible form of cytochrome P-450 in human liver.

external link
17.

Kleinbloesem CH et al. (1984) Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man.

external link
18.

Elshourbagy NA et al. (1980) Separation, purification, and characterization of a novel form of hepatic cytochrome P-450 from rats treated with pregnenolone-16 alpha-carbonitrile.

external link
19.

Shet MS et al. (1993) Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase.

external link
20.

Chen H et al. (1996) Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect.

external link
21.

Lown KS et al. (1997) Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.

external link
22.

Thummel KE et al. (1998) In vitro and in vivo drug interactions involving human CYP3A.

external link
23.

Rebbeck TR et al. (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.

external link
24.

Lehmann JM et al. (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions.

external link
25.

Felix CA et al. (1998) Association of CYP3A4 genotype with treatment-related leukemia.

external link
26.

Paris PL et al. (1999) Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients.

external link
27.

Goodwin B et al. (1999) The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module.

external link
28.

Walker AH et al. (1998) Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online.

external link
29.

Xie W et al. (2000) Humanized xenobiotic response in mice expressing nuclear receptor SXR.

external link
30.

Kittles RA et al. (2002) CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification?

external link
31.

Goodwin B et al. (2002) Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor.

external link
32.

Zeigler-Johnson CM et al. (2002) Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4.

external link
33.

Tirona RG et al. (2003) The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4.

external link
34.

Dimaraki EV et al. (2003) Troglitazone induces CYP3A4 activity leading to falsely abnormal dexamethasone suppression test.

external link
35.

Masuyama H et al. (2003) Expression and potential roles of pregnane X receptor in endometrial cancer.

external link
36.

Markowitz JS et al. (2003) Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme.

external link
37.

Loukola A et al. (2004) Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2.

external link
38.

Gupta RP et al. (2004) CYP3A4 is a human microsomal vitamin D 25-hydroxylase.

external link
39.

Williams PA et al. (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone.

external link
40.

Hirota T et al. (2004) Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status.

external link
41.

Gupta RP et al. (2005) CYP3A4 is a vitamin D-24- and 25-hydroxylase: analysis of structure function by site-directed mutagenesis.

external link
42.

Schirmer M et al. (2006) Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations.

external link
43.

Ekroos M et al. (2006) Structural basis for ligand promiscuity in cytochrome P450 3A4.

external link
44.

van Herwaarden AE et al. (2007) Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.

external link
45.

Idle JR et al. (2000) Medical implications of HGP's sequence of chromosome 22.

external link
46.

Nakamura K et al. (2002) CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability.

external link
47.

Nelson DR et al. (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants.

external link
48.

Gasche Y et al. (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism.

external link
49.

Gaedigk A et al. (1991) Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.

external link
50.

Koren G et al. (2006) Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother.

external link
51.

Desmeules J et al. (1991) Impact of environmental and genetic factors on codeine analgesia.

external link
52.

Gough AC et al. (1990) Identification of the primary gene defect at the cytochrome P450 CYP2D locus.

external link
53.

Hanioka N et al. (1990) The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site.

external link
54.

Kagimoto M et al. (1990) Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.

external link
55.

Chen X et al. (1995) The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease.

external link
56.

Johansson I et al. (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.

external link
57.

Panserat S et al. (1994) DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers.

external link
58.

Saxena R et al. (1994) Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.

external link
59.

Broly F et al. (1995) A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency.

external link
60.

Steen VM et al. (1995) Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene.

external link
61.

Marez D et al. (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution.

external link
62.

Yue QY et al. (1997) Quantification of the O- and N-demethylated and the glucuronidated metabolites of codeine relative to the debrisoquine metabolic ratio in urine in ultrarapid, rapid, and poor debrisoquine hydroxylators.

external link
63.

Vistisen K et al. (1992) Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine.

external link
64.

Ikeya K et al. (1989) Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression.

external link
65.

Butler MA et al. (1989) Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines.

external link
66.

Sesardic D et al. (1988) A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking.

external link
67.

Guengerich FP et al. (1986) Human-liver cytochromes P-450 involved in polymorphisms of drug oxidation.

external link
68.

None (1967) Acetophenetidin sensitivity.

external link
69.

Devonshire HW et al. (1983) The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition.

external link
70.

Shimada T et al. (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

external link
71.

Schweikl H et al. (1993) Expression of CYP1A1 and CYP1A2 genes in human liver.

external link
72.

Liang HC et al. (1996) Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism.

external link
73.

Buters JT et al. (1996) Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2.

external link
74.

Nakajima M et al. (1999) Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans.

external link
75.

Sachse C et al. (1999) Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine.

external link
76.

Tantcheva-Poór I et al. (1999) Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test.

external link
77.

Christiansen L et al. (2000) Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda.

external link
78.

Rasmussen BB et al. (2002) The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors.

external link
79.

Wooding SP et al. (2002) DNA sequence variation in a 3.7-kb noncoding sequence 5' of the CYP1A2 gene: implications for human population history and natural selection.

external link
80.

Browning SL et al. (2010) CYP1A2 is more variable than previously thought: a genomic biography of the gene behind the human drug-metabolizing enzyme.

external link
81.

Thum T et al. (2000) Gene expression in distinct regions of the heart.

external link
82.

Lessard E et al. (1997) Role of CYP2D6 in the N-hydroxylation of procainamide.

external link
83.

Lessard E et al. (1999) Involvement of CYP2D6 activity in the N-oxidation of procainamide in man.

external link
84.

Tucker GT et al. (1977) Polymorphic hydroxylation of debrisoquine.

external link
85.

Heim MH et al. (1992) Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6.

external link
86.

Heim M et al. (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.

external link
87.

Kimura S et al. (1989) The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.

external link
88.

Matsunaga E et al. (1989) The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats.

external link
89.

Skoda RC et al. (1988) Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.

external link
90.

Gonzalez FJ et al. (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.

external link
91.

Gonzalez FJ et al. (1988) Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22.

external link
92.

Eichelbaum M et al. (1987) Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22.

external link
93.

Gonzalez FJ et al. (1987) Debrisoquine 4-hydroxylase: characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism.

external link
94.

Harmer D et al. (1986) The relationship between the acetylator and the sparteine hydroxylation polymorphisms.

external link
95.

Eichelbaum M et al. (1986) The genetic polymorphism of sparteine metabolism.

external link
96.

Nebert DW et al. (1987) The P450 gene superfamily: recommended nomenclature.

external link
97.

Eichelbaum M et al. (1985) Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans.

external link
98.

Distlerath LM et al. (1984) Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme.

external link
99.

Dahl ML et al. (1995) Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.

external link
100.

Agúndez JA et al. (1995) Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population.

external link
101.

Mura C et al. (1993) DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers.

external link
102.

Johansson I et al. (1994) Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.

external link
103.

Bertilsson L et al. (1993) Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine.

external link
104.

Gough AC et al. (1993) Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis.

external link
105.

Daly AK et al. (1996) Nomenclature for human CYP2D6 alleles.

external link
106.

Nelson DR et al. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.

external link
107.

None (1997) Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?

external link
108.

Sachse C et al. (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

external link
109.

McLellan RA et al. (1997) Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians.

external link
110.

Tyndale RF et al. (1997) Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence.

external link
111.

Mikus G et al. (1998) Relevance of deficient CYP2D6 in opiate dependence.

external link
112.

Lundqvist E et al. (1999) Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes.

external link
113.

Bathum L et al. (1998) Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.

external link
114.

Tateishi T et al. (1999) Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population.

external link
115.

Brown MA et al. (2000) Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis.

external link
116.

Payami H et al. (2001) Parkinson's disease, CYP2D6 polymorphism, and age.

external link
117.

Elbaz A et al. (2004) CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease.

external link
118.

Deng Y et al. (2004) Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease.

external link
119.

Liou YH et al. (2006) The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.

external link
120.

Pilotto A et al. (2009) Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease.

external link
121.

Schroth W et al. (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

external link
Update: 26. August 2020
Copyright © 2005-2020 Zentrum für Nephrologie und Stoffwechsel, Dr. Mato Nagel
Albert-Schweitzer-Ring 32, D-02943 Weißwasser, Deutschland, Tel.: +49-3576-287922, Fax: +49-3576-287944
Seitenüberblick | Webmail | Haftungsausschluss | Datenschutz